Barcelona Clinic Liver Cancer Group (BCLC; Translational Research Laboratory and Liver Unit), Hospital Clínic, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Catalonia, Spain.
Barcelona Clinic Liver Cancer Group (BCLC; Translational Research Laboratory and Liver Unit), Hospital Clínic, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Catalonia, Spain; Mount Sinai Liver Cancer Program (Division of Liver Diseases, Department of Medicine; Tisch Cancer Institute), New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.
J Hepatol. 2012 May;56(5):1198-1200. doi: 10.1016/j.jhep.2011.11.014. Epub 2011 Dec 13.
We present the analysis of the evolution of tumors in a case of hepatocellular carcinoma. This case is particularly informative about cancer growth dynamics and the underlying driving mutations. We sampled nine different sections from three tumors and seven more sections from the adjacent nontumor tissues.Selected sections were subjected to exon as well as whole-genome sequencing. Putative somatic mutations were then individually validated across all nine tumor and seven nontumor sections. Among the mutations validated, 24 were amino acid changes; in addition, 22 large indels/copy number variants (>1 Mb) were detected. These somatic mutations define four evolutionary lineages among tumor cells. Separate evolution and expansion of these lineages were recent and rapid, each apparently having only one lineage-specific protein coding mutation. Hence, by using a cell-population genetic definition,this approach identified three coding changes (CCNG1, P62,and an indel/fusion gene) as tumor driver mutations. These three mutations, affecting cell cycle control and apoptosis, are functionally distinct from mutations that accumulated earlier, many of which are involved in inflammation/immunity or cell anchoring. These distinct functions of mutations at different stages may reflect the genetic interactions underlying tumor growth.
我们呈现了一个肝细胞癌病例中肿瘤演变的分析。这个病例对于癌症生长动力学和潜在的驱动突变提供了特别有价值的信息。我们从三个肿瘤中选取了九个不同的切片,并从相邻的非肿瘤组织中选取了七个切片进行分析。选取的切片进行了外显子和全基因组测序。随后在所有九个肿瘤和七个非肿瘤切片中单独验证了疑似体细胞突变。在验证的突变中,有 24 个是氨基酸变化;此外,还检测到 22 个大的插入缺失/拷贝数变异(>1 Mb)。这些体细胞突变在肿瘤细胞中定义了四个进化谱系。这些谱系的独立进化和扩张是最近发生的,而且非常迅速,每个谱系显然只有一个谱系特异性的蛋白编码突变。因此,通过使用细胞群体遗传定义,这种方法确定了三个编码改变(CCNG1、P62 和一个插入缺失/融合基因)为肿瘤驱动突变。这三个突变影响细胞周期控制和细胞凋亡,与早期积累的突变在功能上不同,其中许多突变涉及炎症/免疫或细胞锚定。不同阶段突变的不同功能可能反映了肿瘤生长背后的遗传相互作用。